Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
ARB

Azilsartan medoxomil

Brand names: Edarbi

Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) used in the treatment of essential hypertension.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Its active moiety selectively blocks the angiotensin II type-1 (AT1) receptor, producing vasodilatation and reducing aldosterone-mediated sodium and water retention.

Prescribing in practice

  • Contraindicated in pregnancy because angiotensin receptor blockers can cause fetal toxicity, particularly in the second and third trimesters.
  • Can cause hyperkalaemia and deterioration in renal function, especially in renal impairment, volume depletion or when combined with other renin-angiotensin system agents.
  • Avoid concurrent use with aliskiren in patients with diabetes or moderate-to-severe renal impairment.

Monitoring

Monitor blood pressure, renal function and serum potassium, particularly after initiation and dose changes.

Counselling the patient

  • Tell your prescriber immediately if you become pregnant, as this medicine should be stopped.
  • Rise slowly when starting, as dizziness can occur, and attend for blood tests as advised.

Evidence & guidelines

Azilsartan medoxomil's antihypertensive efficacy is established in clinical trials and supported by the SPC.

Reference: NICE NG136; ESC HT; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Drugs
Pathways